<DOC>
	<DOCNO>NCT00358293</DOCNO>
	<brief_summary>Nightly administration 8 mg unique sublingual ( tongue ) formulation tizanidine , know anti-spasticity medication , show previous study improve next-day spasticity , 12 hour follow dose 20 multiple sclerosis ( MS ) patient . This improvement statistically significant compare oral tizanidine dosing . The current study undertaken see increase dose 12 mg nightly result even great improvement , long effect , i.e. , next day improvement spasticity morning well late afternoon .</brief_summary>
	<brief_title>Study Nighttime Dosing Sublingual Tizanidine ( 12 mg ) Multiple Sclerosis ( MS ) Patients With Significant Spasticity</brief_title>
	<detailed_description>Sublingual tizanidine , novel test formulation know effective antispasticity agent , show unique pharmacokinetic profile [ ( i.e. , nearly twice bioavailability/AUC ) , little increase peak plasma level ( Cmax ) compare oral tizanidine ( Zanaflex ) ] . When administer nightly 20 MS patient , dose 8 mg , show improve next-day spasticity ( statistically significant improvement Ashworth score ) 12 hour post-dosing ) , improvement nighttime ( first quartile ) sleep efficiency ( demonstrated actigraphic measurement ) , increase daytime somnolence . Current study undertaken evaluate increase dosing ( 12 mg nightly ) sublingual tizanidine ( vs. oral ) show concomitant increase clinical effect , i.e. , longer improvement , next-day spasticity score improvement AM ( previously ) well PM ( late afternoon ) evaluation , increase daytime somnolence .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Male female patient age 2065 Definitive diagnosis MS , Expanded Disability Status Scale ( EDSS ) less 6.5 screening Has significant spasticity ( total Ashworth = &gt; 6 ) screening Can maintain sleep regimen least 5 hour nightly study duration May allow take antispasticity medication study ( include oral baclofen ) per individual dosing regimen , follow qualification : No dose 6pm study day No dose clinic evaluation day ( Visits 3 , 4 , 5 ) Females must agree use medically accept form birth control , surgically sterile , two year postmenopausal . Oral contraception contraindicate tizanidine use . Acute MS exacerbation require treatment steroid within 30 day screen Initiation discontinuation interferon beta within 30 day screen Use baclofen pump Use CYP1A2 inhibitor study Taking medication would potentially interfere action study medication outcome variable , include : sedative , stimulant , antihypertensive , tricyclic antidepressant , etc . Previous diagnosis sleep disorder , distinct MS , obstructive sleep apnea narcolepsy Score &gt; 18 Beck Depression Inventory screening Changes chronic oral medication within 2 week baseline study Significant abnormalities screen lab parameter ( ex : ALT , AST , bilirubin &gt; 2 x upper limit normal [ ULN ] ; creatinine &gt; 2 mg/dl ; white blood cell [ WBC ] &lt; 2,300 ; platelet &lt; 80,000 ) . Previous history dementia , unstable psychiatric disease , current sign symptom significant medical disorder severe , progressive , uncontrolled renal , hepatic , hematological , endocrine , pulmonary , cardiac , neurological , cerebral disease History allergy tizanidine inactive component ( include lactose intolerance ) test reference formulation History substance abuse within past 12 month Within 30 day baseline , work rotate nighttime shift Participation another clinical trial within 30 day baseline Patients uncooperative unwilling sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Spasticity</keyword>
	<keyword>Sublingual Tizanidine</keyword>
	<keyword>Ashworth Scores</keyword>
	<keyword>Spasticity Multiple Sclerosis Patients</keyword>
</DOC>